Walgreens, the Illinois-based pharmacy giant, is facing significant financial difficulties, with its stock price having decreased by 80% over the past five years. Currently trading at approximately $11 per share, down from about $56 in July 2019, the company plans to shut down a quarter of its 8,600 U.S. stores by 2027, as revealed in a recent earnings call. Despite a slight increase in revenue and net income during the three months ending May 31, the company has adjusted its earnings-per-share guidance, which does not inspire much confidence.
Compounding these challenges, Walgreens has decided to close 160 VillageMD primary care clinics, an initiative which experts like Stephanie Davis of Barclays believe was a significant margin drag on the company’s assets. Peter Ax, CEO of UpScriptHealth, highlighted that the pharmacy’s issues extend from the front of the store, dealing with theft and labor shortages, to the back where competition from low-cost generics and pharmacy discount cards has reduced margins.
Moreover, industry challenges related to supply chain issues and consumer cost consciousness persist, impacting revenue growth and delaying investment in new technologies essential for remaining competitive. However, there may be a silver lining. Walgreens welcomed a new CEO, Tim Wentworth, in October. Wentworth is focused on streamlining costs and optimizing the company’s profitability. His approach includes cutting the dividend and planning significant store closures to manage costs better.
Experts like Hal Andrews of Trilliant Health and Peter Ax of UpScriptHealth believe that Wentworth’s strategy of returning focus to Walgreens’ core pharmacy and retail operations while retreating from the primary care space may be the key to the company’s turnaround. This perspective is bolstered by recent moves to expand specialty pharmacy services and invest in next-generation technologies.
While the path to recovery may be challenging, investors and industry analysts remain cautiously optimistic that with the right strategic moves, Walgreens could rebound from its current financial straits. Detailed insights into these developments can be found in the original article by MedCity News.